Correlogic Systems of Bethesda, Md., has received US Patent No. 7,395,160, “Quality assurance/quality control for electrospray ionization processes.” The patent describes a method of quality assurance and quality control for high-throughput bioassay processes. The method includes generating a bioassay process model, and then comparing spectral data based on a combination of a biochip and a test serum to the bioassay process model to determine if the test sample and the bioassay process are producing acceptable data. Alternatively, the method may include comparing spectral data based on a combination of serum and diluents used in an electrospray process to the bioassay process model. If the bioassay process and test sample fall within the model, then the spectrum produced may be further analyzed, the patent’s abstract states.
Eppendorf Array Technology of Namur, Belgium, has received US Patent, 7,396,643, “Method for the screening, the detection and/or the quantification of transcriptional factors.” The patent claims a method for the screening, detection, and quantification of transcriptional factors possibly present in a biological sample. The method comprises the steps of: a) extracting and isolating a transcriptional factor from a biological sample; b) contacting the transcriptional factor with a double-stranded DNA sequence bound to an insoluble solid support; and c) detecting and quantifying the fixed transcriptional factor.
Modular Genetics of Cambridge, Mass., and Boston University have received US Patent No. 7,396,646, “Alien sequences.” The patent provides sequences and reagents for preparing microarrays with internal controls. Specifically, the patent defines and provides sequences that are not present in the hybridizing mRNA or cDNA, and therefore can be used both as hybridization controls and for inter-spot normalization. The method for generating these alien sequences includes the steps of: a) providing a naturally occurring sequence; b) determining one or more natural sequence statistics of the naturally occurring sequence; c) applying a hidden Markov model algorithm to the one or more natural sequence statistics of the naturally occurring sequence to generate an alien sequence; d) generating and displaying the alien sequence, with the proviso that, at an adjustable frequency, at least one of the natural sequence statistics of the naturally occurring sequence is switched to a sequence statistic that is inversely proportional to the natural sequence statistic, so that the alien sequence comprises intermittent highly improbable sequence patterns or subsequences throughout its length.
Enzo Life Science of Farmingdale, NY, has received US Patent No. 7,396,647, “Site- or sequence-specific process for cleaving analytes and library of analytes.” The patent claims compositions for use in real-time nucleic acid detection processes. Such real-time nucleic acid detection processes are carried out with energy transfer elements attached to nucleic acid primers, nucleotides, nucleic acid probes, or nucleic acid binding agents. According to the patent, real-time nucleic acid detection allows for the qualitative or quantitative detection or determination of single-stranded or double-stranded nucleic acids of interest in a sample. Other processes are provided, including processes for removing a portion of a homopolymeric sequence from an analyte or library of analytes. Compositions useful in carrying out such removal processes are also described and provided.
Applera has received US Patent No. 7,398,171, “Automated quality control method and system for genetic analysis.” The patent describes a method and apparatus for automating quality control for gene expression data where a computer-based device receives gene expression data associated with a spectral species and genetic sample in each well of a plate. Gene expression data may be received from a sequence detection instrument performing one or more gene expression-related operations for each of the wells of the plate. The computer-based device identifies gene expression data determined to have anomalous characteristics according to a set of one or more quality control metrics and may conditionally flag one or more wells of the plate affected by the anomalous characteristics. Filters can then be selectively applied to temporarily or permanently remove the flagged data from subsequent gene expression studies.